Featured Article Archive
ICR drug discovery highlighted for patient impact
Drug discovery research by ICR scientists has been singled out by a leading cancer journal for the current and future impact it is having on patients, and will be the subject of a presentation at an international cancer conference.
Young ICR scientists win European research award
Two up-and-coming ICR scientists have taken first and third prize in a Europe-wide cancer research competition.
Medical research can be a slow process, but the past decade of intensive work into prostate cancer is happily now starting to pay off.
Vital Funding Continues for Cancer Research
The Royal Marsden NHS Trust, and academic partner, The Institute of Cancer Research (ICR), have been successful in their bid to retain their status as the UK’s only Specialist Biomedical Research Centre (BRC) for Cancer.
Landmark Ovarian Cancer Discovery as Scientists Unveil High Risk Gene
Scientists have discovered that women who carry a faulty copy of a gene called RAD51D have almost a one in 11 chance of developing ovarian cancer, the most significant ovarian cancer gene discovery for more than a decade.
New Type of Hormone Therapy Extends Prostate Cancer Patients’ Lives, Study Finds
The drug abiraterone acetate gave men with advanced prostate cancer an average of four months of extra life, according to Phase III trial results.
The Art of Structural Biology: modelling the APC Complex.
Professor David Barford leads a team within the Section of Structural Biology that has recently published work in the prestigious scientific journal Nature* examining the structure of a protein complex known as the anaphase-promoting complex (APC/C).
Looking Inside The Cell: 3D-modelling a Key Molecule Involved in Cancer Development
The research teams in the ICR’s Section of Structural Biology apply techniques of X-ray crystallography, electron microscopy, biophysics, biochemistry and molecular biology to understand the physical characteristics of proteins and other molecules in the body that are involved in cancer development.
New Research a Step Towards Exciting New Non-Surgical Cancer Treatment
Researchers at The Institute of Cancer Research (ICR) are investigating a new technique that would destroy cancer cells without the need for surgery.
The Institute of Cancer Research names Professor Alan Ashworth FRS as new CEO
Europe’s leading cancer research centre, The Institute of Cancer Research (ICR), has named eminent scientist Professor Alan Ashworth as its new Chief Executive. Professor Ashworth will take up the appointment in January.
Educating the Next Generation of Researchers at The Institute of Cancer Research
In the ICR’s mission to relieve suffering due to cancer, major strategies include both education and the furthering of knowledge through scientific advancement. The programme of postgraduate research and taught training at the ICR both reflects these strategies and forms part of a commitment to the current and future pursuit of excellence in the fight against cancer.
BRCA2 – From Bench to Bedside and Back Again
The ICR and The Royal Marsden NHS Foundation Trust work in partnership to produce high quality basic research and translational studies, with the aim of developing better treatments for the benefit of cancer patients worldwide.
Novel BRAF Inhibitors
In 2002 the ICR began a drug discovery programme funded by The Wellcome Trust, to develop novel inhibitors of the enzyme BRAF, mutations in the B-RAF gene that codes for this enzyme are found in 7 per cent of human cancers, including some colorectal, ovarian and thyroid cancers.
